PARIS, FRANCE (UroToday.com) - The symposium was chaired by Prof. Emmanuel Chartier-Kastler, who, along with his colleagues, has over 10 years experience in the use of Botox treatment for patients with MS and spinal cord injuries.
They shared their personal experiences as well as new findings of the Phase III study called DIGNITY: Double-blind investigation of purified neurotoxin complex for neurogenic detrusor overactivity. Results in this population showed that Botox significantly reduced UI and improved UDS findings and was found to be superior to placebo.
The speakers provided case studies, shared their methodology for performing injections, and cited some common complications - including urinary retention. It was interesting to note that in several MS patient presentations, a decrease in recurrent UTIs was a finding.
Symposium sponsored by Allergan.
Presented at the 13th International European Association of Urology Nurses (EAUN) Meeting - February 24 - 28, 2012 - Le Palais des Congrès de Paris, Paris, France